ArticleMolecular medicine reports2019

Identification of CD4+ T cell biomarkers for predicting the response of patients with relapsing‑remitting multiple sclerosis to natalizumab treatment.

Paolo Fagone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.